Recent Updates
Recently added Catalysts
STOK Positive Sentiment

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Key Takeaway: Stoke Therapeutics announced the grant of stock options for 99,050 shares effective November 16, 2026. The company is advancing its investigational medicine, zorevunersen, aimed at treating Dravet syndrome. This move aligns with their commitment to RNA medicine and restoring protein expression.

Market Sentiment Analysis

POSITIVE FACTORS

  • Stoke Therapeutics granted stock options to employees.
  • The company is focused on RNA medicine.
  • Zorevunersen is in development for Dravet syndrome.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+16%
120-day peak, hindsight
Typical move
6.8%
average across 5 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
zorevunersen
Phase 3 · Dravet Syndrome

Full Press Release Details

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on November 16, 2026, it granted stock options to purchase an aggregate of 99,050 shares of common stock to ele

Frequently Asked Questions

What stock options did Stoke Therapeutics grant?

Stoke Therapeutics granted stock options to purchase 99,050 shares.

When are the stock options effective?

The stock options are effective on November 16, 2026.

What is zorevunersen developed for?

Zorevunersen is a potential treatment for Dravet syndrome.

What is the focus of Stoke Therapeutics?

The company focuses on restoring protein expression with RNA medicine.

Last updated: Nov 17, 2026